More Press Releases

View Older Stories View Newer Stories

Dec 8, 2024 09:30PM FPT and RWE Sign 5-Year Master Service Agreement to Drive Innovation and Sustainability

Dec 8, 2024 09:27PM Aura Minerals Announces Positive Exploration Results from Multiple High-Potential Projects

Dec 8, 2024 09:00PM At Harvard Symposium, Squirrel Ai's Dr. Joleen Liang Forecasts the Next Chapter in AI-Driven Education

Dec 8, 2024 09:00PM Global Total Semiconductor Equipment Sales Forecast to Reach a Record of $139 Billion in 2026, SEMI Reports

Dec 8, 2024 09:00PM Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024

Dec 8, 2024 09:00PM Lead Real Estate Co., Ltd. Opening New Apartment Hotel, ENT TERRACE GINZA PREMIUM, in Tokyo

Dec 8, 2024 08:12PM Fuel Logic Launches Newly Designed Website to Enhance Nationwide Diesel Fuel Delivery Experience

Dec 8, 2024 08:11PM Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’

Dec 8, 2024 08:11PM Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’

Dec 8, 2024 08:00PM Apple announces Apple Retail expansion in the Kingdom of Saudi Arabia

Dec 8, 2024 08:00PM Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeti

Dec 8, 2024 07:42PM Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Dec 8, 2024 07:31PM New Results Show Donor Search Prognosis Score Equalizes Transplant Outcomes at American Society of Hematology Annual Meeting 2024

Dec 8, 2024 07:30PM Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows

Dec 8, 2024 07:30PM DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagn

Dec 8, 2024 07:30PM Orca Bio Presents Three-Year Survival Data with Orca-T® in Patients with Hematological Malignancies at the 66th ASH Annual Meeting

Dec 8, 2024 07:20PM Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

Dec 8, 2024 07:02PM AI Tool Fight Health Insurance Goes Viral, Empowering Everyone to Challenge Denied Claims

Dec 8, 2024 06:00PM Breaking Barriers in Data Communication: ULVAC & SAL join forces

Dec 8, 2024 07:00PM Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024

Dec 8, 2024 05:00PM Paynet.red: Instant Etisalat Recharge, E-Vouchers & Packages

Dec 8, 2024 03:30PM Tony Van Heugten, CTO of e-Vision Smart Optics, Inc., inducted in the 2024 Florida Inventors Hall of Fame

Dec 8, 2024 03:00PM AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients

Dec 8, 2024 03:00PM SK Life Science, Inc. Presents XCOPRI® (cenobamate tablets) CV Data at the AES 2024 Annual Meeting Showing a Deeper Understanding of Cenobamate's Dual Mechanism of Action

Dec 8, 2024 03:00PM Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse L

Dec 8, 2024 01:58PM WTCH 24 - Countless historical results and a new superpower emerged

Dec 8, 2024 01:45PM Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at Americ

Dec 8, 2024 12:52PM Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

Dec 8, 2024 12:40PM Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Dec 8, 2024 12:33PM TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

Dec 8, 2024 12:30PM Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma

Dec 8, 2024 12:30PM Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Dec 8, 2024 12:30PM Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

Dec 8, 2024 12:30PM bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Expositio

Dec 8, 2024 12:30PM C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Dec 8, 2024 12:30PM Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Dec 8, 2024 12:30PM Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Dec 8, 2024 12:05PM Apple Sued for Knowingly Hosting Child Sexual Abuse Material on Its Products, Failing to Protect Survivors

Dec 8, 2024 12:00PM Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Dec 8, 2024 12:00PM Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Dec 8, 2024 12:00PM ReAlta Life Sciences Announces Positive Preclinical Data for RLS-0071 (pegtarazimod) in Acute Graft-Versus-Host Disease (aGVHD) at American Society of Hematology Annual Meeting

Dec 8, 2024 12:00PM Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Dec 8, 2024 11:58AM Scryb Launches New AI Governance Technology Business Unit, 'Raidian'

Dec 8, 2024 11:50AM Global Times: People's Daily article says favorable conditions for China's economic development remain unchanged

Dec 8, 2024 11:29AM Storyinstanavigation Ranks the Top 5 Best Instagram Story Viewers Online

Dec 8, 2024 11:21AM DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

Dec 8, 2024 11:09AM CWTI Provides Revised Update on Canada Postal Strike Delay Mailing of the Company's 2024 Annual General Meeting Materials

Dec 8, 2024 11:00AM Studies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions

Dec 8, 2024 11:00AM Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

Dec 8, 2024 11:00AM Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leuke

View Newer Stories View Older Stories